Identification

Name
Praziquantel
Accession Number
DB01058  (APRD01196, EXPT02728)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

An anthelmintic used in most schistosome and many cestode infestations.

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BiltricideTablet, film coated600 mg/1OralBayer2011-04-21Not applicableUs
BiltricideTablet, film coated600 mg/1OralDepartment Of State Health Services, Pharmacy Branch2016-11-18Not applicableUs
BiltricideTablet, film coated600 mg/1OralCentral Texas Community Health Centers2011-04-21Not applicableUs
BiltricideTablet600 mgOralBayer1997-04-24Not applicableCanada
BiltricideTablet, film coated600 mg/1OralAvera Mc Kennan Hospital2015-05-27Not applicableUs
International/Other Brands
Biltricide
Categories
UNII
6490C9U457
CAS number
55268-74-1
Weight
Average: 312.4061
Monoisotopic: 312.183778022
Chemical Formula
C19H24N2O2
InChI Key
FSVJFNAIGNNGKK-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
IUPAC Name
2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one
SMILES
O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1

Pharmacology

Indication

For the treatment of infections due to all species of schistosoma.

Structured Indications
Pharmacodynamics

Praziquantel is an anthelmintic used in most schistosome and many cestode infestations. Praziquantel effects the permeability of the cell membrane resulting in the contraction of schistosomes. The drug further causes vacuolization and disintegration of the schistosome tegument. The effect is more marked on adult worms compared to young worms. An increased calcium influx may play an important role. Secondary effects are inhibition of glucose uptake, lowering of glycogen levels and stimulation of lactate release. The action of praziquantel is limited very specifically to trematodes and cestodes; nematodes (including filariae) are not affected.

Mechanism of action

Praziquantel works by causing severe spasms and paralysis of the worms' muscles. This paralysis is accompanied - and probably caused - by a rapid Ca 2+ influx inside the schistosome. Morphological alterations are another early effect of praziquantel. These morphological alterations are accompanied by an increased exposure of schistosome antigens at the parasite surface. The worms are then either completely destroyed in the intestine or passed in the stool. An interesting quirk of praziquantel is that it is relatively ineffective against juvenile schistosomes. While initially effective, effectiveness against schistosomes decreases until it reaches a minimum at 3-4 weeks. Effectiveness then increases again until it is once again fully effective at 6-7 weeks. Glutathione S-transferase (GST), an essential detoxification enzyme in parasitic helminths, is a major vaccine target and a drug target against schistosomiasis. Schistosome calcium ion channels are currently the only known target of praziquantel.

TargetActionsOrganism
ASchistosome calcium ion (Ca2+) channels
other/unknown
Schistosoma
Absorption

Rapidly absorbed (80%)

Volume of distribution
Not Available
Protein binding

80 to 85%

Metabolism

renal

Route of elimination
Not Available
Half life

0.8-1.5 hours (in serum)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Praziquantel can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Praziquantel can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Praziquantel can be decreased when it is combined with Amodiaquine.Approved, Investigational
AprepitantThe serum concentration of Praziquantel can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Praziquantel can be decreased when combined with Armodafinil.Approved, Investigational
AtazanavirThe metabolism of Praziquantel can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Praziquantel can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Praziquantel can be decreased when combined with Azithromycin.Approved
BoceprevirThe metabolism of Praziquantel can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Praziquantel can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Praziquantel can be decreased when it is combined with Bosentan.Approved, Investigational
CaffeineThe metabolism of Praziquantel can be decreased when combined with Caffeine.Approved
CarbamazepineThe serum concentration of Praziquantel can be decreased when it is combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Praziquantel can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Praziquantel can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Praziquantel can be decreased when it is combined with Chloroquine.Approved, Vet Approved
CholecalciferolThe metabolism of Praziquantel can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.Approved
CitalopramThe metabolism of Praziquantel can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Praziquantel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Praziquantel can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Praziquantel can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Praziquantel can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Praziquantel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Praziquantel can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Praziquantel can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Praziquantel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Praziquantel can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Praziquantel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Praziquantel can be decreased when combined with Delavirdine.Approved
DihydroergotamineThe metabolism of Praziquantel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Praziquantel can be decreased when combined with Diltiazem.Approved
DosulepinThe metabolism of Praziquantel can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Praziquantel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Praziquantel can be decreased when combined with Dronedarone.Approved
EfavirenzThe metabolism of Praziquantel can be decreased when combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Praziquantel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Praziquantel can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Praziquantel can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe metabolism of Praziquantel can be decreased when combined with Etravirine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.Approved
FluconazoleThe metabolism of Praziquantel can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Praziquantel can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Praziquantel can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Praziquantel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Praziquantel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Praziquantel can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Praziquantel can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Praziquantel can be decreased when combined with Gemfibrozil.Approved
HydroxychloroquineThe serum concentration of Praziquantel can be decreased when it is combined with Hydroxychloroquine.Approved
ImatinibThe metabolism of Praziquantel can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Praziquantel can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Praziquantel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Praziquantel can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Praziquantel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Praziquantel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Praziquantel can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Praziquantel can be increased when it is combined with Ketoconazole.Approved, Investigational
LidocaineThe metabolism of Praziquantel can be decreased when combined with Lidocaine.Approved, Vet Approved
LobeglitazoneThe metabolism of Praziquantel can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Praziquantel can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Praziquantel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Praziquantel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Praziquantel can be decreased when it is combined with Lumacaftor.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Praziquantel.Approved, Investigational
MexiletineThe metabolism of Praziquantel can be decreased when combined with Mexiletine.Approved
MidostaurinThe metabolism of Praziquantel can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Praziquantel can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Praziquantel can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Praziquantel can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Praziquantel can be decreased when combined with Modafinil.Approved, Investigational
NefazodoneThe metabolism of Praziquantel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Praziquantel can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Praziquantel can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Praziquantel can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Praziquantel can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Praziquantel can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Praziquantel can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Praziquantel can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Praziquantel can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Praziquantel can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Praziquantel can be decreased when combined with Pantoprazole.Approved
Peginterferon alfa-2bThe serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Praziquantel can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Praziquantel can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Praziquantel can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Praziquantel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquineThe serum concentration of Praziquantel can be decreased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Praziquantel can be decreased when it is combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Praziquantel can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Praziquantel can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Praziquantel can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Praziquantel can be decreased when it is combined with Rifapentine.Approved
RopiniroleThe metabolism of Praziquantel can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Praziquantel can be decreased when combined with Saquinavir.Approved, Investigational
SertralineThe metabolism of Praziquantel can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Praziquantel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Praziquantel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Praziquantel can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Praziquantel can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Praziquantel can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Praziquantel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Praziquantel can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Praziquantel can be decreased when combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Praziquantel can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Praziquantel can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Praziquantel.Approved, Withdrawn
TiclopidineThe metabolism of Praziquantel can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.Approved
TopiramateThe metabolism of Praziquantel can be decreased when combined with Topiramate.Approved
TranylcypromineThe metabolism of Praziquantel can be decreased when combined with Tranylcypromine.Approved
VenlafaxineThe metabolism of Praziquantel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Praziquantel can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Praziquantel can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Praziquantel can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Praziquantel can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take with food.

References

General References
  1. Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67. doi: 10.1097/QCO.0b013e328318978f. [PubMed:18978535]
  2. McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008 Jan;21(1):225-42. doi: 10.1128/CMR.00046-07. [PubMed:18202444]
External Links
Human Metabolome Database
HMDB15191
KEGG Drug
D00471
KEGG Compound
C07367
PubChem Compound
4891
PubChem Substance
46507082
ChemSpider
4722
BindingDB
74574
ChEBI
91583
ChEMBL
CHEMBL976
Therapeutic Targets Database
DAP000695
PharmGKB
PA164764583
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Praziquantel
ATC Codes
P02BA01 — Praziquantel
AHFS Codes
  • 08:08.00 — Anthelmintics
FDA label
Download (152 KB)
MSDS
Download (72.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSchistosomiasis [Bilharziasis]1
2CompletedTreatmentIntestinal Schistosomiasis1
2CompletedTreatmentSchistosoma infection1
2RecruitingTreatmentSchistosoma infection1
2, 3CompletedTreatmentEpilepsies / Neurocysticercosis1
2, 3CompletedTreatmentSchistosoma Haematobium1
3CompletedPreventionHealthy Volunteers1
3CompletedTreatmentSchistosoma Hematobium Infection / Schistosomiasis Mansoni1
3CompletedTreatmentSchistosoma Mansoni1
3CompletedTreatmentSchistosoma infection1
3Not Yet RecruitingTreatmentNeurocysticercosis1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) / Schistosomiasis Mansoni1
4CompletedTreatmentSchistosomiasis Mansoni1
4Not Yet RecruitingBasic ScienceSchistosoma infection1
4Not Yet RecruitingTreatmentSchistosoma infection1
Not AvailableActive Not RecruitingNot AvailableUro-genital Schistosomiasis1
Not AvailableCompletedNot AvailableSchistosoma Haematobium / Sexually Transmitted Infections (STIs)1
Not AvailableCompletedPreventionAnemias / Hepatosplenomegaly / Plasmodium Infections1
Not AvailableCompletedTreatmentBilharzia / Schistosoma infection1
Not AvailableCompletedTreatmentHelminthiasis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHematuria / Hydronephrosis1
Not AvailableCompletedTreatmentParasitic Diseases2
Not AvailableCompletedTreatmentPlasmodium Infections / Schistosoma infection1
Not AvailableCompletedTreatmentSchistosoma Mansoni1
Not AvailableRecruitingOtherTaenia solium infection / Tenia Solium Infection1
Not AvailableTerminatedTreatmentHelminthiasis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusPreventionAnemias / Hematologic Diseases / Infection, Human Immunodeficiency Virus I / Intestinal Helminthiasis / Intestinal Schistosomiasis / Opportunistic Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral600 mg
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Biltricide 600 mg tablet14.57USD tablet
Praziquantel powder1.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)136 °CPhysProp
water solubility400 mg/LMERCK INDEX (1996)
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.381 mg/mLALOGPS
logP2.42ALOGPS
logP2.3ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)19.38ChemAxon
pKa (Strongest Basic)-0.22ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity88.79 m3·mol-1ChemAxon
Polarizability34.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.974
Blood Brain Barrier+0.9939
Caco-2 permeable+0.5496
P-glycoprotein substrateSubstrate0.7237
P-glycoprotein inhibitor IInhibitor0.8052
P-glycoprotein inhibitor IINon-inhibitor0.9113
Renal organic cation transporterInhibitor0.5469
CYP450 2C9 substrateNon-substrate0.8505
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5805
CYP450 1A2 substrateInhibitor0.846
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5401
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9637
BiodegradationNot ready biodegradable0.9413
Rat acute toxicity2.0726 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8291
hERG inhibition (predictor II)Non-inhibitor0.5813
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0019000000-066af1bbcb832fac2ff4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0092000000-2572aab54fdc9ff2617e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0790000000-bba67a778d41524cdf76
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00e9-0910000000-412442e38f79438b5893
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0089-0900000000-b663739905edd86c61cb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ik9-0049000000-02c2bbc25fcb21061ef8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2190000000-eca5b2601627401a5544
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f89-8980000000-5102a741f0625afd5c7a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-5910000000-2a141277a2d28d23bfd0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-4900000000-77a7f036670b581c354c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-3900000000-21cde0d9fc368991b837
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0019000000-9fdf91e83d7fd02342cc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0092000000-0dbdbc1e5a8153d5764a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0490000000-472ed6570d02d80aef23
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fl0-0920000000-4b4b7e731ba9ab20d076
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0089-0900000000-c5ff862373e835bc247f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0w29-0598000000-5f9aeabd10ef70166cb6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ik9-2698000000-8cf56d1fd2138bc420ec

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Tetrahydroisoquinolines
Sub Class
Not Available
Direct Parent
Tetrahydroisoquinolines
Alternative Parents
Alpha amino acids and derivatives / N-alkylpiperazines / Benzenoids / Tertiary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Alpha-amino acid or derivatives / Tetrahydroisoquinoline / N-alkylpiperazine / 1,4-diazinane / Piperazine / Benzenoid / Tertiary carboxylic acid amide / Lactam / Carboxamide group / Carboxylic acid derivative
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

1. Schistosome calcium ion (Ca2+) channels
Kind
Group
Organism
Schistosoma
Pharmacological action
Yes
Actions
Other/unknown
References
  1. Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67. doi: 10.1097/QCO.0b013e328318978f. [PubMed:18978535]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18